Ivan Burkov
Principal @ Inkef
Ivan Burkov is a seed investor at Inkef focused on Therapeutics and Biotechnology. Ivan Burkov
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ivan Burkov invests in
Stages Ivan Burkov invests in
Countries Ivan Burkov invests in
Investment Focus
Industry
- Therapeutics 2 (100%)
- Biotechnology 2 (100%)
- Health Care 1 (50%)
- Medical Device 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Seed 1 (50%)
- Series B 1 (50%)
Country
- Denmark 1 (50%)
- The Netherlands 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $60.1M / Series B / May 27, 2025 | |
|
|
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases. | $13.2M / Seed / Jul 17, 2024 |
Co-Investors
About Inkef
Inkef is a venture capital firm based in Amsterdam, backing promising early stage companies in Europe. Inkef takes pride in being a patient, long-term investor with the ability to support companies through several rounds of funding. From the early stages of a technology or life science venture, Inkef supports entrepreneurs building their ideas intosuccessful international businesses.Investment areas: Technology and Healthcare
Inkef Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Frank Lansink
Partner
|
|||
|
Thijs Cohen Tervaert
Partner
|
|||
|
Derk Arts
Founder
|
|||
|
Ivan Burkov
Principal
|
|||
|
Simone Botti
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ivan Burkov invest in?
Ivan Burkov invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ivan Burkov last invest?
The most recent investment recorded for Ivan Burkov closed in May 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!